Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 5/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11756402 | 0.81 | BTK (0.46) | BTKJAK3PLCG1 | |
| SCHEMBL28898521 | 0.80 | TGM2 (0.40) | ENPP2KDM4E | |
| SCHEMBL4775243 | 0.80 | ENPP2 (0.42) | ENPP2KDM4EALDH1A1MGLL | |
| SCHEMBL19890630 | 0.79 | HSD17B1 (0.51) | BTKJAK3KDM4E | |
| SCHEMBL7820160 | 0.79 | ENPP2 (0.44) | ENPP2KDM4EALDH1A1MGLL | |
| SCHEMBL15088204 | 0.79 | ALDH1A1 (0.53) | BTKJAK3ALDH1A1PLCG1FGFR4 | |
| SCHEMBL7779064 | 0.78 | HTR3E (0.54) | BTKBCL2A1ALDH1A1FGFR4 | |
| SCHEMBL15974825 | 0.78 | BTK (0.46) | BTKJAK3BCL2A1ALDH1A1PLCG1 | |
| SCHEMBL29989323 | 0.78 | BTK (0.46) | BTKJAK3BCL2A1ALDH1A1PLCG1 | |
| SCHEMBL18229115 | 0.76 | BTK (0.42) | BTKJAK3KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212216-A1 | SYNTHESIS OF LACTONE DERIVATIVES AND THEIR USE IN THE MODIFICATION OF PROTEINS | GENIE BIOTECH UK LTD. (GB) | 2023-07-06 | — | — | US | disclosed |
| EP-4076533-A1 | SYNTHESIS OF LACTONE DERIVATIVES AND THEIR USE IN THE MODIFICATION OF PROTEINS | GENIE BIOTECH UK LTD. (GB) | 2022-10-26 | — | — | EP | disclosed |
| WO-2021123229-A1 | SYNTHESIS OF LACTONE DERIVATIVES AND THEIR USE IN THE MODIFICATION OF PROTEINS | GENIE BIOTECH UK LTD. (GB) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212216-A1 | SYNTHESIS OF LACTONE DERIVATIVES AND THEIR USE IN THE MODIFICATION OF PROTEINS | AGL, PGLS, DDOST | BTK 998/4885ENPP2 2148/4885JAK3 2420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.